Wednesday , November 22 2017
Home / 2015 / June

Monthly Archives: June 2015

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

TORONTO, June 24, 2015 /PRNewswire/ — CSL Behring today presented data from Phase III studies evaluating the efficacy and long-term safety of its investigational long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).  The data, shared in three separate oral presentations at the 2015 International Society on Thrombosis …

Read More »

Diplomat Expands Hepatitis C Specialty Services with Acquisition of Burman’s Specialty Pharmacy

FLINT, Mich. – June 19, 2015 – Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today it has acquired Burman’s Specialty Pharmacy (Burman’s). Burman’s, located in the greater Philadelphia, Pennsylvania area, is a provider of individualized patient care with a primary focus on the challenging condition of hepatitis C. “Burman’s shares our strong commitment to …

Read More »

Dell and TGen Extend Partnership in Precision Medicine Effort

IT provider Dell Inc. has extended its partnership with the Translational Genomics Research Institute (TGen) to assist researchers and physicians expand the reach and impact of precision medicine efforts for pediatric cancer. The companies announced their extended partnership, aimed at helping clinical researchers and physicians expand globally the reach and …

Read More »

Novartis’ Promacta Approved for Children with a Rare Blood Disorder

US health regulators expanded approval of Novartis’ Promacta to treat children with a rare blood disorder. Novartis said that the US Food and Drug Administration (FDA) approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to …

Read More »

Starting Up in the Biosimilars Market: Oncobiologics’ CEO, Pankaj Mohan, on the Company’s Path to Success

In the race to bring biosimilar products to the market, many industry experts predict that pharma giants will be the winners.  However, some emerging biotech companies, such as Oncobiologics, have dared to enter the sector among the established players. How will they survive? At the “Biosimilars 20/20” conference in Philadelphia, …

Read More »

Leading the Way for Biosimilars: Managed Care’s Lonely Road

By Kathleen P. Wolff, MBA Specialty Pharma Journal Forging a pathway of innovation is typically easier with friends and allies. But these days, in the world of biosimilars, where stakeholders are still sizing each other up, allies are scarce. At the Biosimilars 20/20 conference in Philadelphia, the consensus among key opinion …

Read More »

Hospira Presents Positive Results for its Biosimilar Monoclonal Antibody Inflectra

Biosimilars drugmaker Hospira, Inc. announced results showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Janssen’s Remicade to Hospira’s Inflectra, the first biosimilar monoclonal antibody, which received approval from the European Commission (EC) in 2013. The Lake Forest-based company presented the data at the European …

Read More »

FDA Grants Breakthrough Therapy Designation to Actemra for Systemic Sclerosis

US health regulators have granted Breakthrough Therapy designation to Genentech’s Actemra (tocilizumab) for systemic sclerosis. Genentech, a member of the Roche Group, said that the US Food and Drug Administration (FDA) has granted Breakthrough status to Actemra for systemic sclerosis, also known as scleroderma, a rare, chronic disorder characterized by …

Read More »

Cures for (Nearly) All

Even those with the most severe cases of hepatitis C could have a future without this virus. New direct-acting antiviral medications for treating hepatitis C continue to bring healing potential to a wide variety of hepatitis C patients. Most recently, two new studies in the Journal of the American Medical Association show …

Read More »